{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:23:17Z","timestamp":1740147797936,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11899-021-00609-5","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T16:06:26Z","timestamp":1614614786000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?"],"prefix":"10.1007","volume":"16","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-7313","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"609_CR1","first-page":"227","volume-title":"Aggressive lymphomas","author":"A Broccoli","year":"2019","unstructured":"Broccoli A, Chihara D, Fanale M, Zinzani PL. Standard of care in T cell lymphoma. In: Lenz G, Salles G, editors. Aggressive lymphomas. Cham: Springer; 2019. p. 227\u201344."},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2.","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2017.05.008","volume":"58","author":"P Martin","year":"2017","unstructured":"Martin P, Ghione P, Dreyling. Mantle cell lymphoma\u2013current standards of care and future directions. Cancer Treat Rev. 2017;58:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.008.","journal-title":"Cancer Treat Rev"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","volume":"34","author":"SV Adams","year":"2016","unstructured":"Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34:963\u201371. https:\/\/doi.org\/10.1200\/JCO.2015.63.5540.","journal-title":"J Clin Oncol"},{"key":"609_CR5","doi-asserted-by":"publisher","unstructured":"\u2022 Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558The paper states that expert hematopathology reveiw is important for accurate diagnosis of PTCL.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089.","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570\u20137. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"key":"609_CR7","doi-asserted-by":"publisher","unstructured":"\u2022 Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20:323\u201342. https:\/\/doi.org\/10.1038\/s41568-020-0247-0The paper discusses that the overall survival of patients with PTCLs will dramatically increased by combining new targeted agents with immune regulators and chimeric antigen receptor-expreesing natural killer and T cell.","DOI":"10.1038\/s41568-020-0247-0"},{"key":"609_CR8","doi-asserted-by":"publisher","unstructured":"\u2022 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569Reference consensus among hematopathologists. geneticists, and clinicians regarding both updated to current entities as well as the addition of a limited number of new provisional entities in lymphoid malignancies.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1038\/bcj.2014.34.","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214. https:\/\/doi.org\/10.1038\/bcj.2014.34.","journal-title":"Blood Cancer J"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443.","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicentre cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdu443.","journal-title":"Ann Oncol"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2404306.","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2404306.","journal-title":"Leukemia"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022.","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Escoda L, Estany C, Cam\u00f3s M, et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958\u201363. https:\/\/doi.org\/10.1093\/annonc\/mdn022.","journal-title":"Ann Oncol"},{"key":"609_CR13","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicentre study. J Clin Oncol. 2009;27:106\u201313. https:\/\/doi.org\/10.1200\/JCO.2008.17.4870Clinically study on the role of ASCT in first line for PTCL.","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"609_CR14","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452. https:\/\/doi.org\/10.1038\/bcj.2016.63Clinically study on the role of ASCT in first line for PTCL.","DOI":"10.1038\/bcj.2016.63"},{"key":"609_CR15","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.40.2719Clinically study on the role of ASCT in first line for PTCL.","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"609_CR16","doi-asserted-by":"publisher","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019;125:1507-1517. doi: https:\/\/doi.org\/10.1002\/cncr.31861.","DOI":"10.1002\/cncr.31861."},{"issue":"suppl 1","key":"609_CR17","doi-asserted-by":"publisher","first-page":"464 abstr","DOI":"10.1182\/blood-2019-122781","volume":"134","author":"KJ Savage","year":"2019","unstructured":"Savage KJ, Horwitz SM, Advani RH, Christensen JH, Domingo-Domenech E, Rossi G, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. Blood (ASH Annual Meeting Abstracts). 2019;134(suppl 1):464 abstr. https:\/\/doi.org\/10.1182\/blood-2019-122781.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl 5","key":"609_CR18","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201.","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, W-S Kim LS, et al. ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315. https:\/\/doi.org\/10.1093\/annonc\/mdv201.","journal-title":"Ann Oncol"},{"key":"609_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.bbmt.2015.12.004.","volume":"22","author":"J El-Asmar","year":"2016","unstructured":"El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, et al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed\/refractory setting: a systematic review\/meta-analysis. Biol Blood Marrow Transplant. 2016;22:802\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.004.","journal-title":"Biol Blood Marrow Transplant"},{"key":"609_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787.","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdx787.","journal-title":"Ann Oncol"},{"key":"609_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.24372.","volume":"91","author":"C Yam","year":"2016","unstructured":"Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672\u20136. https:\/\/doi.org\/10.1002\/ajh.24372.","journal-title":"Am J Hematol"},{"key":"609_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41408-017-0030-y.","volume":"7","author":"T Tang","year":"2017","unstructured":"Tang T, Khoo LP, Lim C, Ham JS, Kim SJ, Hong H, et al. Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. Blood Cancer J. 2017;7:653. https:\/\/doi.org\/10.1038\/s41408-017-0030-y.","journal-title":"Blood Cancer J"},{"key":"609_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organizationsubtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"609_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.14699.","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703\u20136. https:\/\/doi.org\/10.1111\/bjh.14699.","journal-title":"Br J Haematol"},{"key":"609_CR25","doi-asserted-by":"publisher","unstructured":"Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol. 2019;8(2). https:\/\/doi.org\/10.1186\/s40164-019-0126-0.","DOI":"10.1186\/s40164-019-0126-0."},{"issue":"6","key":"609_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710\u201325. https:\/\/doi.org\/10.1002\/ajh.25487.","journal-title":"Am J Hematol"},{"issue":"6","key":"609_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37(6):471\u201380.","journal-title":"J Clin Oncol"},{"key":"609_CR28","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.clml.2017.02.021.","volume":"17S","author":"AD Staton","year":"2017","unstructured":"Staton AD, Langston AA. Autologous stem cell transplant: still the standard for fit patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17S:S96\u20139. https:\/\/doi.org\/10.1016\/j.clml.2017.02.021.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10044","key":"609_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dosecytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388(10044):565\u201375.","journal-title":"Lancet"},{"issue":"1","key":"609_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13929","volume":"173","author":"P Armand","year":"2016","unstructured":"Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al. A phase 2 study of rituximab-Bendamustine and rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89\u201395.","journal-title":"Br J Haematol"},{"key":"609_CR31","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Drandi D, Alcantara M, Benmaad I, S\u00f6hlbrandt A, Lhermitte L, Zaccaria G, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network. Hemasphere. 2020;4(2):e347. https:\/\/doi.org\/10.1097\/HS9.0000000000000347The papaer describes the increasing investigation of MRD in MCL.","DOI":"10.1097\/HS9.0000000000000347"},{"key":"609_CR32","doi-asserted-by":"crossref","unstructured":"\u2022 Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250\u201360 This article reviews the of rituximab after ASCT in MCL.","DOI":"10.1056\/NEJMoa1701769"},{"key":"609_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hon.2596.","volume":"37","author":"S Rule","year":"2019","unstructured":"Rule S. The modern approach to mantle cell lymphoma. Hematol Oncol. 2019;37:66\u20139. https:\/\/doi.org\/10.1002\/hon.2596.","journal-title":"Hematol Oncol"},{"key":"609_CR34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92:806\u201313. https:\/\/doi.org\/10.1002\/ajh.24797.","journal-title":"Am J Hematol"},{"key":"609_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/blood.V128.22.145.145","volume":"128","author":"S Le Gouill","year":"2016","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the LYSA\/Goelams group. Blood. 2016;128:145.","journal-title":"Blood"},{"issue":"28","key":"609_CR36","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013\u201323.","journal-title":"J Clin Oncol"},{"issue":"12","key":"609_CR37","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34(12):1386\u201394.","journal-title":"J Clin Oncol"},{"key":"609_CR38","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","volume":"24","author":"S Bernstein","year":"2013","unstructured":"Bernstein S, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, et al. A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma: SWOG 0213. Ann Oncol. 2013;24:1587\u201393.","journal-title":"Ann Oncol"},{"key":"609_CR39","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"609_CR40","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of MCL after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a randomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"609_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Eskelund CW, Gronbaek K, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310 The article suggests that patients with MCL should be stratified according to TP53 status.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"609_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"609_CR43","unstructured":"\u2022 Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367 The paper reports on the pahase II study suggesting an important role for acalabrutinib in the treatment of MCL."},{"key":"609_CR44","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256\u201369.","journal-title":"J Clin Oncol"},{"key":"609_CR45","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"},{"key":"609_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183:578\u201387.","journal-title":"Br J Haematol"},{"key":"609_CR47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study. Hematol Oncol. 2017;35:528\u201335.","journal-title":"Hematol Oncol"},{"key":"609_CR48","doi-asserted-by":"publisher","unstructured":"\u2022 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347The paper describes the remarkable clinical outcome of anti-CD19 chimeric antigen receptor T cells in treating MCL.","DOI":"10.1056\/NEJMoa1914347"},{"key":"609_CR49","doi-asserted-by":"publisher","unstructured":"\u2022 Stirrups R. CAR T-cell therapy for relapsed or refractory mantle-cell lymphoma. Lancet Oncol. 2020;21:e239. https:\/\/doi.org\/10.1016\/S1470-2045(20)30231-XThe paper comments on the especially impressive results of CAR-T cell therapy study for MCL.","DOI":"10.1016\/S1470-2045(20)30231-X"},{"key":"609_CR50","doi-asserted-by":"publisher","unstructured":"\u2022 Jain P, Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)-outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020. https:\/\/doi.org\/10.1002\/ajh.25796Study indicating that venetoclax resistance in MCL is predominantly associated with non-BCL2 gene mutations.","DOI":"10.1002\/ajh.25796"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00609-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T19:33:06Z","timestamp":1618947186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00609-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"1 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandro Broccoli, Lisa Argnani, and Pier Luigi Zinzani declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}